ACECLOFENAC

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H13Cl2NO4
Molecular Weight	354.185
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)COC(=O)CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl

InChI

InChIKey=MNIPYSSQXLZQLJ-UHFFFAOYSA-N

InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)

HIDE SMILES / InChI

Molecular Formula	C16H13Cl2NO4
Molecular Weight	354.185
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugs.com/pro/clanza-cr.html

Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) analog of Diclofenac. It is used for the relief of pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The dose is 100 mg twice daily, and should not be given to people with porphyria or breastfeeding mothers and is not recommended for children. Aceclofenac is a cytokine inhibitor. Aceclofenac works by blocking the action of a substance in the body called cyclo-oxygenase. Cyclo-oxygenase is involved in the production of prostaglandins (chemicals in the body which cause pain, swelling and inflammation). Aceclofenac is the glycolic acid ester of diclofenac. The incidence of gastric ulcerogenicity of aceclofenac has been reported to be significantly lower than that of other frequently prescribed NSAIDs: for instance, 2-fold less than naproxen, 4-fold less than diclofenac, and 7-fold less than indomethacin. Aceclofenac is metabolized in human hepatocytes and human microsomes to form [2-(2',6'-dichloro-4'-hydroxy- phenylamino)phenyl] acetoxyacetic acid as the major metabolite, which is then further conjugated.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18547825	Inhibitor 8504		3.0 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 320 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3	Palliative	Approved 8583	Clanza CR Approved Use CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date 2011
Ankylosing spondylitis 33 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3	Palliative	Approved 8583	Clanza CR Approved Use CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date 2011
Osteoarthritis of scapulohumerous 1 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3	Palliative	Approved 8583	Clanza CR Approved Use CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date 2011
Periarthritis of scapulohumerous 1 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3	Palliative	Approved 8583	Clanza CR Approved Use CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date 2011

C_max

Value	Dose	Analyte	Population
10700.18 ng/mL OTHER GOV'T https://mhraproducts4853.blob.core.windows.net/docs/b3d28f88fd5c2a58da9fe9c222d07115029b119b	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.629 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32898192/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22149151/	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22149151/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22149151/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT

AUC

Value	Dose	Analyte	Population
20814.17 ng × h/mL OTHER GOV'T https://mhraproducts4853.blob.core.windows.net/docs/b3d28f88fd5c2a58da9fe9c222d07115029b119b	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
23.272 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32898192/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22149151/	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22149151/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22149151/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT

T_1/2

Value	Dose	Analyte	Population
3.841 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32898192/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22149151/	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22149151/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22149151/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ACECLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% OTHER https://www.medicines.org.uk/emc/product/4240/smpc#PHARMACOKINETIC_PROPS			ACECLOFENAC plasma	Homo sapiens

Doses

Dose	Population	Adverse events
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23581533/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23581533/	Disc. AE: Dyspepsia, Nausea... AEs leading to discontinuation/dose reduction: Dyspepsia (0.34%) Nausea (0.34%) Abdominal pain (0.34%) Sources: https://pubmed.ncbi.nlm.nih.gov/23581533/
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8829889/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8829889/	Disc. AE: Gastralgia, Epigastralgia... AEs leading to discontinuation/dose reduction: Gastralgia (1.85%) Epigastralgia (1.2%) Pyrosis (0.62%) Diarrhoea (0.62%) Abdominal pain (0.62%) Melena (0.62%) Hepatic enzymes increased (0.62%) Pruritis (0.62%) Erythema (0.62%) Vertigo (0.62%) Dyspnoea (0.62%) Haematocrit abnormal (0.62%) Sources: https://pubmed.ncbi.nlm.nih.gov/8829889/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438 substrate 1193	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP2A6 879 MRP2 499 MRP3 246 CYP1A2 2153 CYP2E1 1060 MRP4 290 BSEP 550 CYP19A1 429	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNjQ1In19	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNjQ1In19	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNjQ1In19	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTM2NDUifX0=	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNjQ1In19	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTM2NDUifX0=	no [IC50 >10 uM]
MRP3 326	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNjQ1In19	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNjQ1In19	no [IC50 >133 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71771#section=BioAssay-Results Page: 357.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71771#section=BioAssay-Results Page: 401.0	no
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNjQ1In19	weak [IC50 105 uM]
CYP2C9 2497	inhibitor 4027 Sources: eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNjQ1In19	yes [IC50 1.5849 uM]
MRP2 625	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNjQ1In19	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27839691/	major
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71771#section=BioAssay-Results Page: 400 \| 402	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71771#section=BioAssay-Results Page: 5.0

PubMed

Title	Date	PubMed
Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis.	2008-12	18547825
Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia.	2008-10	18644036
Vesicular aceclofenac systems: a comparative study between liposomes and niosomes.	2008-10	18608811
Preparation and, in vitro, preclinical and clinical studies of aceclofenac spherical agglomerates.	2008-10	18606224
Simultaneous determination of aceclofenac, paracetamol, and chlorzoxazone by RP-HPLC in pharmaceutical dosage form.	2008-08	18718143
Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion.	2008-07-09	18613981
A simple and sensitive stability-indicating RP-HPLC assay method for the determination of aceclofenac.	2008-05-22	18492356
Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal.	2008-04-15	18383398
Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene.	2008-04-15	18076062
Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers.	2008-04	18498912
Preventing peridural fibrosis with nonsteroidal anti-inflammatory drugs.	2008-03	18172695
Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behçet's disease.	2008-02-29	18306487
Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach.	2008-02-28	17945447
Simultaneous determination of aceclofenac and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry.	2008-02-13	18096348
Mathematical evaluation of similarity factor using various weighing approaches on aceclofenac marketed formulations by model-independent method.	2008-01	18271300
Chitosan and enteric polymer based once daily sustained release tablets of aceclofenac: in vitro and in vivo studies.	2008	18500561
Evaluation of SLS: APG mixed surfactant systems as carrier for solid dispersion.	2008	18459049
Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation.	2008	18446476
Nanoemulsions as vehicles for transdermal delivery of aceclofenac.	2007-12-14	18181525
Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial.	2007-08	17387026
[After taking non-steroidal anti-inflammatory agents. What is the cause of the "blue spot?" ].	2007-07-19	17703681
Improved bioavailability of aceclofenac from spherical agglomerates: development, in vitro and preclinical studies.	2007-07	17545107
Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom.	2007-06	18360631
Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?	2007-05-20	17239835
Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.	2007-05-20	17134688
Photodegradation and in vitro phototoxicity of aceclofenac.	2007-05	17557739
Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction?	2007-05	17518513
Fixed drug eruption due to aceclofenac.	2007-05	17441860
In vitro effects of non-steroidal anti-inflammatory drugs on cytokine, prostanoid and matrix metalloproteinase production by interface membranes from loose hip or knee endoprostheses.	2007-05	17188523
Influence of amorphous cyclodextrin derivatives on aceclofenac release from directly compressible tablets.	2007-04	17484283
Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY.	2007-03	18188417
High-performance liquid chromatography and pharmacokinetics of aceclofenac in rats.	2007-02-28	17386653
Preparation, in vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac.	2007-02	17366745
Physicochemical characterization and dissolution enhancement of aceclofenac-hydroxypropyl beta-cyclodextrin binary systems.	2007-01-31	17260903
Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses.	2007-01	17328244
Allergic contact dermatitis due to aceclofenac.	2006-12	17101014
Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.	2006-12	16687434
The efficacy and safety of aceclofenac versus placebo and naproxen in women with primary dysmenorrhoea.	2006-12	16675091
Evaluation of bioequivalence of two formulations containing 100 milligrams of aceclofenac.	2006-11-09	17090444
Consumption costs of inappropriate medicines estimated from bulk purchase data: The example of NSAids in Guatemala.	2006-11	17176623
[Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs].	2006-10-07	17022718
Topical delivery of aceclofenac from lecithin organogels: preformulation study.	2006-10	17076644
[A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor].	2006-09	16998298
Generalized pustular psoriasis precipitated by aceclofenac.	2006-09	16922973
Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems.	2006-08	16867024
Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac.	2006-08	16476713
Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience.	2006-05	16709320
Anaphylactic reaction after aceclofenac intake.	2006-04	16512820
Effect of processing variables on micro particulate system of aceclofenac.	2006-01	16632445
Comparative efficacy of aceclofenac and etoricoxib in post extraction pain control: randomized control trial.	2005-12-24	16372792

Patents

Sample Use Guides

In Vivo Use Guide

is 200 mg daily, taken as one dose (every 24 hours).

Route of Administration: Oral

In Vitro Use Guide

In vitro adhesion assays were developed to examine the effects of aceclofenac on both neutrophil adhesion to tumor necrosis factor alpha stimulated human umbilical vein endothelial cells under nonstatic conditions, and homotypic neutrophil aggregation induced by anti-ICAM-3 and anti-CD18 monoclonal antibodies (Mab)

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:08:49 GMT 2025` Edited by `admin` on `Mon Mar 31 18:08:49 GMT 2025`
Record UNII	RPK779R03H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACECLOFENAC [EP MONOGRAPH]

Preferred Name

English

ACECLOFENAC

Official Name

English

Aceclofenac betadex [WHO-DD]

Common Name

English

ACECLOFENAC [MART.]

Common Name

English

GLYCOLIC ACID, (O-(2,6-DICHLOROANILINO)PHENYL)ACETATE (ESTER)

Common Name

English

Aceclofenac [WHO-DD]

Common Name

English

ACECLOFENAC [MI]

Common Name

English

aceclofenac [INN]

Common Name

English

ACECLOFENAC [JAN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM02AA25